296 related articles for article (PubMed ID: 20424613)
1. Criteria for evaluation of disease extent by (123)I-metaiodobenzylguanidine scans in neuroblastoma: a report for the International Neuroblastoma Risk Group (INRG) Task Force.
Matthay KK; Shulkin B; Ladenstein R; Michon J; Giammarile F; Lewington V; Pearson AD; Cohn SL
Br J Cancer; 2010 Apr; 102(9):1319-26. PubMed ID: 20424613
[TBL] [Abstract][Full Text] [Related]
2. Revisions to the International Neuroblastoma Response Criteria: A Consensus Statement From the National Cancer Institute Clinical Trials Planning Meeting.
Park JR; Bagatell R; Cohn SL; Pearson AD; Villablanca JG; Berthold F; Burchill S; Boubaker A; McHugh K; Nuchtern JG; London WB; Seibel NL; Lindwasser OW; Maris JM; Brock P; Schleiermacher G; Ladenstein R; Matthay KK; Valteau-Couanet D
J Clin Oncol; 2017 Aug; 35(22):2580-2587. PubMed ID: 28471719
[TBL] [Abstract][Full Text] [Related]
3. The new international neuroblastoma response criteria.
Orr KE; McHugh K
Pediatr Radiol; 2019 Oct; 49(11):1433-1440. PubMed ID: 31620844
[TBL] [Abstract][Full Text] [Related]
4. Extending positron emission tomography scan utility to high-risk neuroblastoma: fluorine-18 fluorodeoxyglucose positron emission tomography as sole imaging modality in follow-up of patients.
Kushner BH; Yeung HW; Larson SM; Kramer K; Cheung NK
J Clin Oncol; 2001 Jul; 19(14):3397-405. PubMed ID: 11454888
[TBL] [Abstract][Full Text] [Related]
5. Evaluation of the utility of
Gauguet JM; Pace-Emerson T; Grant FD; Shusterman S; DuBois SG; Frazier AL; Voss SD
Pediatr Blood Cancer; 2017 Nov; 64(11):. PubMed ID: 28449267
[TBL] [Abstract][Full Text] [Related]
6. [123I-metaiodobenzylguanidine (MIBG) scintigraphy for the staging of neuroblastoma].
Okuyama C; Ushijima Y; Sugihara H; Okitsu S; Maeda T
Kaku Igaku; 1998 Nov; 35(9):835-42. PubMed ID: 9916399
[TBL] [Abstract][Full Text] [Related]
7. Iodine-131-metaiodobenzylguanidine and bone scintigraphy for the detection of neuroblastoma.
Shulkin BL; Shapiro B; Hutchinson RJ
J Nucl Med; 1992 Oct; 33(10):1735-40. PubMed ID: 1403138
[TBL] [Abstract][Full Text] [Related]
8. Follow-up in neuroblastoma: comparison of metaiodobenzylguanidine and a chimeric anti-GD2 antibody for detection of tumor relapse and therapy response.
Reuland P; Geiger L; Thelen MH; Handgretinger R; Haase B; Müller-Schauenburg W; Niethammer D; Bares R
J Pediatr Hematol Oncol; 2001 Oct; 23(7):437-42. PubMed ID: 11878578
[TBL] [Abstract][Full Text] [Related]
9. Evaluation of semi-quantitative scoring system for metaiodobenzylguanidine (mIBG) scans in patients with relapsed neuroblastoma.
Messina JA; Cheng SC; Franc BL; Charron M; Shulkin B; To B; Maris JM; Yanik G; Hawkins RA; Matthay KK
Pediatr Blood Cancer; 2006 Dec; 47(7):865-74. PubMed ID: 16444675
[TBL] [Abstract][Full Text] [Related]
10. Correlation of early metastatic response by 123I-metaiodobenzylguanidine scintigraphy with overall response and event-free survival in stage IV neuroblastoma.
Matthay KK; Edeline V; Lumbroso J; Tanguy ML; Asselain B; Zucker JM; Valteau-Couanet D; Hartmann O; Michon J
J Clin Oncol; 2003 Jul; 21(13):2486-91. PubMed ID: 12829667
[TBL] [Abstract][Full Text] [Related]
11. Radioiodinated meta-iodobenzylguanidine in the diagnosis of childhood neuroblastoma.
Claudiani F; Stimamiglio P; Bertolazzi L; Cabria M; Conte M; Villavecchia GP; Garaventa A; Lanino E; De Bernardi B; Scopinaro G
Q J Nucl Med; 1995 Dec; 39(4 Suppl 1):21-4. PubMed ID: 9002744
[TBL] [Abstract][Full Text] [Related]
12. Neuroblastoma: dose-related sensitivity of MIBG scanning in detection.
Parisi MT; Matthay KK; Huberty JP; Hattner RS
Radiology; 1992 Aug; 184(2):463-7. PubMed ID: 1620849
[TBL] [Abstract][Full Text] [Related]
13.
Lewington V; Lambert B; Poetschger U; Sever ZB; Giammarile F; McEwan AJB; Castellani R; Lynch T; Shulkin B; Drobics M; Staudenherz A; Ladenstein R
Eur J Nucl Med Mol Imaging; 2017 Feb; 44(2):234-241. PubMed ID: 27663238
[TBL] [Abstract][Full Text] [Related]
14. Skeletal assessment in neuroblastoma--the pitfalls of iodine-123-MIBG scans.
Gordon I; Peters AM; Gutman A; Morony S; Dicks-Mireaux C; Pritchard J
J Nucl Med; 1990 Feb; 31(2):129-34. PubMed ID: 2313350
[TBL] [Abstract][Full Text] [Related]
15. In-111 pentetreotide scintigraphy in patients with neuroblastoma. Comparison with I-131 MIBG, N-Myc oncogene amplification, and patient outcome.
Shalaby-Rana E; Majd M; Andrich MP; Movassaghi N
Clin Nucl Med; 1997 May; 22(5):315-9. PubMed ID: 9152532
[TBL] [Abstract][Full Text] [Related]
16. Iodine-123 metaiodobenzylguanidine scintigraphy scoring allows prediction of outcome in patients with stage 4 neuroblastoma: results of the Cologne interscore comparison study.
Decarolis B; Schneider C; Hero B; Simon T; Volland R; Roels F; Dietlein M; Berthold F; Schmidt M
J Clin Oncol; 2013 Mar; 31(7):944-51. PubMed ID: 23341514
[TBL] [Abstract][Full Text] [Related]
17. More advantages in detecting bone and soft tissue metastases from prostate cancer using
Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
[TBL] [Abstract][Full Text] [Related]
18. Modern nuclear medicine evaluation of neuroblastoma.
Pflüger T; Schmid I; Coppenrath E; Weiss M
Q J Nucl Med Mol Imaging; 2010 Aug; 54(4):389-400. PubMed ID: 20823807
[TBL] [Abstract][Full Text] [Related]
19. Likelihood of bone recurrence in prior sites of metastasis in patients with high-risk neuroblastoma.
Polishchuk AL; Li R; Hill-Kayser C; Little A; Hawkins RA; Hamilton J; Lau M; Tran HC; Strahlendorf C; Lemons RS; Weinberg V; Matthay KK; DuBois SG; Marcus KJ; Bagatell R; Haas-Kogan DA
Int J Radiat Oncol Biol Phys; 2014 Jul; 89(4):839-45. PubMed ID: 24867534
[TBL] [Abstract][Full Text] [Related]
20. 18F-FDG PET/CT and 123I-metaiodobenzylguanidine imaging in high-risk neuroblastoma: diagnostic comparison and survival analysis.
Papathanasiou ND; Gaze MN; Sullivan K; Aldridge M; Waddington W; Almuhaideb A; Bomanji JB
J Nucl Med; 2011 Apr; 52(4):519-25. PubMed ID: 21421719
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]